摘要
目的:探讨阿托伐他汀对脑卒中患者颈动脉支架置入术(carotid artery stenting,CAS)后对比剂肾病的预防效果。方法:选择天津市环湖医院神经科2015年10月至2018年12月间行CAS治疗的患者,采用随机数字表分组法分为对照组和观察组。对照组术后给予阿司匹林(100 mg·d^-1),氯吡格雷(75 mg·d^-1)治疗。观察组在对照组基础上给予阿托伐他汀(40 mg·d^-1)治疗。比较2组术前、术后1、3、5和7 d的Scr、BUN、Ccr、β2-MG、ALB、hs-CRP指标变化,对比剂肾病及不良事件发生情况。结果:2组患者术前Scr、BUN、Ccr、β2-MG、ALB、hs-CRP比较差异无统计学意义(P>0.05);对照组术后1、3、5和7 d的Scr、BUN、β2-MG、ALB、hs-CRP高于术前,Ccr低于术前(P <0.05);观察组术后1、3、5和7 d的Scr、BUN高于术前(P <0.05),术后1、3、5和7 d Ccr、β2-MG、ALB、hs-CRP与术前比较差异无统计学意义(P>0.05);观察组术后1、3、5和7 d Scr、BUN、β2-MG、ALB、hs-CRP低于对照组,Ccr高于对照组(P<0.05)。观察组对比剂肾病发生率(7.50%)低于对照组(18.75%)(P<0.05)。结论:阿托伐他汀可减轻脑卒中患者CAS术后对比剂对肾功能的损伤,对对比剂肾病的预防效果好。
Objective:To investigate the preventive effect of atorvastatin on contrast-induced nephropathy after carotid artery stenting(CAS) in stroke patients.Methods:Patients who underwent CAS from October 2015 to December 2018 in neurology department of Tianjin Huanhu Hospital were selected.All the patients treated with CAS were divided into control group and observation group with random number table.The control group received aspirin(100 mg·d^-1) and clopidogrel(75 mg·d^-1) after operation.The observation group was treated with atorvastatin(40 mg·d^-1) on the basis of the control group.The changes of SCr,BUN,Ccr,beta 2-MG,ALB and hs-CRP before and 1,3,5 and 7 days after operation,and the occurrence of contrast-induced nephropathy and adverse event rates were compared between the two groups.Results:There was no significant difference in Scr,BUN,Ccr,beta 2-MG,ALB and hs-CRP between the two groups before operation(P>0.05).SCr,BUN,beta 2-MG,ALB,hs-CRP at 1,3,5 and 7 days after operation in the control group were higher than those before operation,Ccr in the control group was lower than those before operation(P <0.05).SCr,BUN at 1,3,5 and 7 days after operation in the observation group were higher than those before operation(P <0.05),There was no significant difference in Ccr,beta 2-MG,ALB and hs-CRP at 1,3,5 and 7 days after operation in the observation group than those before operation(P> 0.05).The levels of Scr,BUN,beta 2-MG,ALB and hs-CRP in the observation group were lower than those in the control group at 1,3,5 and 7 days after operation,while the levels of Ccr in the observation group were higher than those in the control group(P <0.05).The incidence of contrast-induced nephropathy in the observation group was7.50%,which was lower than that in the control group(18.75%)(P <0.05).Conclusion:Atorvastatin can alleviate the damage of contrast agent to renal function in stroke patients after CAS,and has good preventive effect on contrast-induced nephropathy.
作者
乔凌亚
边际
贾强
王世波
徐小林
QIAO Ling-ya;BIAN Ji;JIA Qiang;WANG Shi-bo;XU Xiao-lin(Department of Neurology,Tianjin Huanhu Hospital,Tianjin 300350,China;Department of Neurosurgery,Tianjin Huanhu Hospital,Tianjin 300350,China)
出处
《临床药物治疗杂志》
2019年第10期37-41,共5页
Clinical Medication Journal
基金
天津市卫生局科技基金(2015KY17)
